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SUMMARY
Intermittent preventive treatment of infants (IPTi) with sulphadoxine pyrimethamine (SP) is recommended as an
additional malaria control intervention in high transmission areas of sub-Saharan Africa, provided its protective eﬃcacy is
not compromised by SP resistance. A signiﬁcant obstacle in implementing SP-IPTi, is in establishing the degree of
resistance in an area. Since SP monotherapy is discontinued, no contemporary measures of in vivo eﬃcacy can be made, so
theWorld Health Organisation has recommended a cut-oﬀ based upon molecular markers, stating that SP-IPTi should not
be implemented when the prevalence of the dhps 540Emutation among infections exceeds 50%.We created a geo-referenced
database of SP resistancemarkers in Africa from published literature. By selecting surveys of malaria infected blood samples
conducted since 2004 we have mapped the contemporary prevalence of dhps 540E. Additional maps are freely available in
interactive form at http://www.drugresistancemaps.org/ipti/. Eight countries in East Africa are classiﬁed as unsuitable for
SP-IPTi when data are considered at a national level. Fourteen countries in Central and West Africa were classiﬁed as
suitable while seven countries had no available contemporary data to guide policy. There are clear deﬁciencies in molecular
surveillance data coverage. We discuss requirements for ongoing surveillance of SP resistance markers in support of the use
of SP-IPTi.
Key words: Antimalarial resistance, maps, dhps 540, intermittent preventive treatment infants.
INTRODUCTION
IPTi is a promising intervention for reducing
malaria and anaemia in young children in malaria
endemic countries which can be rolled out within
the World Health Organisation’s (WHO) Expanded
Programme of Immunisation (EPI). A treatment
dose of sulphadoxine pyrimethamine (SP) is given at
the time of routine vaccination of infants and studies
have shown this reduces the incidence of clinical
malaria in under-ones by about 30% (Aponte et al.
2009). The intensiﬁcation of SP resistance in many
parts of Africa has led to concerns that the protective
eﬃcacy will be compromised. Since SP is the only
drug tested for safety, eﬃcacy and EPI interactions,
no alternative drugs are currently available for use
in IPTi.
Randomised controlled trials of IPTi using sul-
phadoxine pyrimethamine reported protective eﬃca-
cies against clinical episodes of malaria ranging from
20% to 59% and against anaemia from 10% to 50% up
to 12 months of age (Schellenberg et al. 2001, 2005;
Chandramohan et al. 2005; Macete et al. 2006;
Mockenhaupt et al. 2007; Grobusch et al. 2007a,b;
Kobbe et al. 2007). The ﬁrst study of IPTi with SP
conducted in Ifakara Tanzania during 1999–2000
showed the highest protection against malaria
(Schellenberg et al. 2001) but resistance has risen
steeply in the following years (Malisa et al. 2010)
raising concerns about eﬃcacy. A later trial in an area
of exceptionally high SP resistance in Northern
Tanzania reported no protective eﬃcacy with SP-
IPTi (Gosling et al. 2009). To examine the relation-
ship between the protective eﬃcacy of SP-IPTi and
resistance, an analysis of seven SP-IPTi trials was
carried out (Griﬃn et al. 2010). Two measures of SP
resistance were used; contemporaneous data from six
in vivo eﬃcacy studies using SP and seven molecular
studies reporting frequency of dhfr triple and dhps
double mutations within 50 km of the trial sites.
The results suggested that there was a reduction in
the protective eﬃcacy of SP-IPTi with increasing
molecular markers of SP resistance.
SP resistance occurs via substitutions in the target
enzymes dihydrofolate reductase (DHFR) and dihy-
dropteroate synthase (DHPS) coded by point
mutations in the dhfr and dhps genes (Cowman et al.
1988; Peterson et al. 1988; Brooks et al. 1994; Triglia
and Cowman, 1994). Mutant dhfr alleles are varied
and code for a range of tolerance to pyrimethamine
from intermediate to high, depending upon the
number of mutations present. The triple mutant
dhfr allele (N51I+C59R+S108N) is a signiﬁcant
contributor to SP treatment failure. It originated in
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Asia (Roper et al. 2004) but now has a pan-African
distribution dating back to the 1980s (Certain et al.
2008; Maiga et al. 2007).
Sulphadoxine resistant dhps emerged during the
1990s, against this background of high level pyr-
imethamine resistance. In East Africa the appearance
of a dhps double mutant A437G+K540E heralded
the arrival of signiﬁcant SP treatment failures in the
region (Naidoo andRoper 2010). The combination of
the dhps double mutant A437G+K540E and the dhfr
triple mutant were shown to be predictive of early SP
treatment failure among malaria patients in Kenya,
Uganda and Malawi (Omar et al. 2001; Staedke et al.
2004; Kublin et al. 2002). InWest and Central Africa
the dhpsK540E mutation is rare but the dhps A437G
single mutant, combined with triple mutant dhfr was
found to be associated with treatment failure in
Gabon (Kun et al. 1999), Ghana (Mockenhaupt et al.
2005), the Gambia (Dunyo et al. 2006) and Republic
of Congo, Brazzaville (Ndounga et al. 2007). An
exception is a study by Marks et al. (2005) in Ghana
who reported no association of A437G with treat-
ment outcome in vivo. Studies done in vitro indicate
that the 437G single mutant confers a lesser degree of
drug tolerance than the A437G and K540E com-
bined (Brooks et al. 1994; Triglia et al. 1997). Hence
it is considered very likely that the consequences for
IPTi eﬃcacy are less severe.
The WHO Technical Consultation on Intermit-
tent Preventive Treatment of Infants (WHO, 2009)
took account of the diﬀering sensitivity of single and
double mutant forms of dhps, noting that 540E
mutations are indicative of high level SP resistance.
A prevalence of 50% of the dhps 540E mutation is the
threshold recommended by WHO to determine
whether or not SP-IPTi should be implemented.
In addition to the dhps 540E, there are two other
mutations which are newly emerging in Africa which,
when found in conjunction with the dhfr triple and
dhps double mutants, indicate extremely high levels
of parasite insensitivity to SP which abrogate SP
eﬃcacy for both IPTi and IPTp. These are the dhfr
164L mutation and the dhps 581G. Harrington et al.
(2009) in a study inMuheza, Tanga region, Tanzania
showed that the eﬃciency of IPTp was largely com-
promised when pregnant women were infected with
parasites expressing the dhps- A437G+K540E+
A581G haplotype. Another recent study at Hale
Health Centre, situated 32 km north of Muheza,
reported 55% prevalence of the same haplotype. The
clinical and parasitological cure rate at day 28 was less
than 20% in children aged 6–59 months treated for
clinical malaria with SP (Gesase et al. 2009). The
establishment of A437G+K540E+A581G may
explain the total lack of protective eﬀect of SP for
IPTi in the same area reported by Gosling et al.
(2009).
Currently there is a need for standardized infor-
mation about the dhps 540E, 581G and dhfr 164L
mutations in African sites where implementation
of SP-IPTi is being used or considered for use. The
purpose of this review is to summarise current
knowledge about the prevalence of the dhps 540E
and 581G and the dhfr 164Lmarkers in a form which
is freely accessible and easily understood. We have
created maps which are available in interactive form
on the worldwide web. They have utility not only in
guiding IPTi – SP policy but also in highlighting
the gaps in surveillance coverage which need to be
addressed.
MATERIALS AND METHODS
Data collection
We conducted online literature searches periodically
during October 2005 to February 2011 using the
Pubmed, African Journal Online and Bioline data-
bases using the search terms ‘malaria’, ‘dhps’ and
‘dhfr’ (Naidoo and Roper, 2010). We included
published studies which had been conducted in any
malarious African country excluding studies of
malaria imported from Africa to non-African
countries, animal studies, vaccine trials, prophylaxis
studies, methodology studies and in vitro studies of
resistance. There were no restrictions applied on the
basis of malaria case detection, age, pregnancy status,
transmission intensity or molecular method used to
detect resistant mutations.
We reviewed the full text of suitable studies and
extracted the prevalence of dhfr and dhps mutations.
Data were ﬁrst written on a proforma containing
predesigned data ﬁelds, including geo-referenced
study site and study year, and subsequently double
entered into a data entry system to ensure quality con-
trol. We recorded the proportion of infections con-
taining individual dhfr or dhps point mutations and
where possible, the haplotypes of associated point
mutations in each gene. The details of studies that
were identiﬁed and included in our analyses are pro-
vided on our website (www.drugresistancemaps.org).
Data analysis
We analysed the prevalence of dhps K540E, A581G
and dhfr I164L. Graphs showing 540E prevalence
through time were generated in Intercooled Stata ver
9.2 with calculated 95% exact binomial conﬁdence
intervals for each study sample. Studies where the
year of sampling was not reported were not included
in the plots of prevalence through time.We generated
graphs to illustrate the prevalence of dhps 540E over a
20 year period, from 1988 to 2009 in six geographical
categories. Pearce et al. (2009) identiﬁed ﬁve geo-
graphical regions of mainland Africa consisting of
neighbouring countries which share the same dhps
resistance allele lineages. In this study, we added a
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sixth cluster consisting of island populations and
these are listed in Table 1.
Vector maps were created in Mapinfo ver 9.0 to
illustrate the spatial distribution of dhfr 164L and
dhps 581G prevalence reports. All studies, including
those whose study year was not stated were included
in these maps. To illustrate the recent prevalence of
540E we selected only those studies where the
samples were collected in 2004 or later and created a
composite map showing sites where 540E was
examined and highlighting those where prevalence
exceeded the recommended threshold of 50%.
RESULTS
Prevalence of the dhps 540E mutation
We identiﬁed 119 publications describing 260 unique
surveys of 540E prevalence which fulﬁlled the
inclusion criteria and these are listed in full in the
supplementary bibliography S1 (see http://journals.
cambridge.org/PAR). The cumulative total number
of isolates tested for 540E was 30224, of which 10339
(36%) tested positive with 540E. The regional
distribution of surveys is summarized in Table 2.
The most intensively studied area was the Southeast
region where 129 surveys were carried out in 83
unique study sites in the 11 Southeast region
countries listed in Table 1. The prevalence of 540E
for successive surveys in each region is plotted with
95% exact binomial conﬁdence intervals in Fig. 1.
The 540E was common in surveys conducted
throughout Southeast and Northeast Africa and its
prevalence, which tended to increase over time, was
seen to approach 100% in some areas. In Northeast
Africa 27 surveys were conducted in 13 unique study
sites in three countries and a prevalence of 100% 540E
was reported at one site in 2004.
In the West, Central, Southwest and Island re-
gions, the prevalence of 540E never exceeded 50%. In
the West we recorded 45 surveys in 35 unique study
sites within 14 countries. Among these the majority
of surveys reported the 540E mutation was rare or
absent, An exception was a reported prevalence of
23% in Ibadan, Nigeria. In the ﬁve countries of the
Southwest region, there were 21 surveys in 16 study
sites and the prevalence of 540E was universally less
than 50%. Within the Central region 21 surveys from
11 diﬀerent study sites all reported 540E prevalences
of under 6%. Similarly the 17 surveys at 12 sites
among island populations reported low prevalences
of 540E and the maximum value recorded was 20% in
2004 in Sao Tome and Principe.
Prevalence of the dhfr 164L mutation
All publications in which surveys of dhfr 164L were
carried out are listed in the supplementary bibli-
ography S2 (see http://journals.cambridge.org/
PAR). Of 19597 isolates tested for 164L in 183
surveys and 114 unique sites, 164L was detected in
just 130 isolates (0·7%). The regional distribution of
the surveys and mutant positive isolates are shown in
Table 2. In Fig. 2 a map illustrating the prevalence of
164L shows all the surveys which examined codon
164 in African parasites. Detection rates for the 164L
mutation ranged from 0·6% to 13·7% of isolates
tested. The 164L mutation was found in the Central
African Republic, Comoros, Kenya, Madagascar,
Malawi, Rwanda and Uganda but was absent in 21
other countries where surveys were conducted.
Prevalence of the dhps 581G mutation
All publications in which surveys of dhps 581G were
carried out are listed in the supplementary biblio-
graphy S3 (see http://journals.cambridge.org/PAR).
Of 15331 isolates tested for 581G in Africa, the
mutation occurred in 782 (5%) isolates in 13 countries
namely Cameroon, Democratic Republic of Congo,
Ethiopia, Ghana, Kenya,Madagascar, Malawi,Mali,
Niger, Rwanda, Sudan, Tanzania and Uganda. The
581G was reported in all the regions except for the
Southwest (Table 2). The survey sites and prevalence
measurements are recorded in the map in Fig. 3
which shows 14 other countries where surveys were
negative. The majority of the surveys recorded
581G<50% although in one study carried out prior
to 1997 in Sotuba, Mali the 581G mutation was
reported to be 100%.
Recent surveys of the dhps 540E resistance marker and
their application for SP-IPTi
To focus on the current situation, a subset of recent
data was selected using only the surveys of dhps 540
Table 1. Regional sub-division of African countries
based on shared dhps resistance lineages (Pearce
et al. 2009) and including islands as a separate
category
Countries
Regional
category
Democratic Republic of Congo (East),
Kenya, Malawi, Mozambique, Rwanda,
South Africa, Swaziland, Tanzania,
Uganda, Zambia, Zimbabwe
Southeast
Djibouti, Ethiopia, Sudan Northeast
Benin, Burkina Faso, Ivory Coast,
Equatorial Guinea, Gambia, Ghana,
Guinea, Guinea-Bissau, Liberia, Mali,
Mauritania, Niger, Nigeria, Senegal
West
Angola, Democratic Republic of Congo
(West), Gabon, Namibia, Republic of
Congo
Southwest
Cameroon, Central African Republic Central
Comoros, Madagascar, Sao Tome/Principe Islands
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carried out between 2004 and 2009. In all, 90 recent
surveys were identiﬁed in which 4243 (35%) of
12167 samples were positive for the 540E mutation.
The regional distribution of these surveys and the
proportion which reported prevalences higher
than the 50% cut-oﬀ are summarised in Table 2,
while their geographical locations are shown in the
map in Fig. 4. The Southeast and Northeast
regions contained all the survey sites with prevalence
of the 540E mutation >50%. Prevalence exceeded
50% in eight countries namely Ethiopia, Kenya,
Uganda, Rwanda, Tanzania, Malawi, Zambia and
Mozambique. Within this subgroup 40 recent
surveys were conducted of which 34 surveys recorded
a prevalence of 50% or more.Exceptions being four
studies in Maputo, Mozambique (2004 6% and 11%,
2005 16%. 2006 49%) and 2 studies in Zambia (Macha
2006 11%, Mpongwe 2004 46%). Within individual
countries surveys recorded broadly consistent pre-
valences of the 540E mutation.
In Ethiopia, three surveys were conducted in
Jimma, Dilla and Humera all in 2004 and these
reported consistently high 540E prevalences of 97%,
97% and 100% respectively (Gebru-Woldearegai
et al. 2005; Schunk et al. 2006; Pearce et al. 2009).
The sites cover a wide area – Jimma and Dilla are
approximately 220 km apart and Humera is 900 km
from Dilla. Although there have been no surveys
published subsequently,and no surveys detected dhfr
164L the extreme prevalence of the 540E in 2004 and
early reports of low level 581G (<2%) indicate that
SP-IPTi is likely to be compromised by drug
resistance in Ethiopia.
In Kenya, nine surveys were carried out in nine
unique sites between 2004 and 2006. The dhps
K540E prevalence was always greater than 50% and
ranged from 74% in Iguhu, Kakamega District to
99% in Kombewa, (these sites are about 12 km apart)
(Bonizzoni et al. 2009; Zhong et al. 2008). There are
reports of dhfr 164L at prevalences around 3% in
western Kenya suggesting that a very highly SP
resistant form might be emerging here (McCollum
et al. 2006).
In Uganda, 540E prevalence has exceeded 50%
since 1999 (Staedke et al. 2004). Surveys conducted
during 2002–2004 in six national surveillance sites
recorded prevalences of between 80% (in Mubende)
and 98% (in Tororo) (Francis et al. 2006), and most
recently dhps 540E prevalences of 98% and 100%were
recorded in Rukungiri and Kabale in 2005 (Lynch
et al. 2008). Overlaid upon dhps 540E there are
emerging foci of dhps 581G (up to 45% prevalence)
and dhfr 164L (up to 14% prevalence) in southwest
Uganda recorded in 2005 (Francis et al. 2006; Lynch
et al. 2008) indicating that SP-IPTi will be severely
compromised by resistance in this area.
In Rwanda, surveys at Rukara and Mashesha in
2005 and reported prevalences of 97% and 84% 540E
respectively (Karema et al. 2010). The same surveys
revealed emergence of the dhfr 164L (12%) and dhps
581G (61%) at Rukara which is approximately
120 km from the highly resistant populations
Table 2. Prevalence of dhps K540E, dhps A581G and dhfr I164L
Southeast Northeast Central West Southwest Islands All Regions
All surveys of K540E
number of surveys 129 27 21 45 21 17 260
samples tested for K540E 18751 1537 2109 4573 1976 1278 30224
samples positive for 540E 9531 609 9 65 95 30 10339
unique sites surveyed 83 13 11 35 16 12 170
countries surveyed 11 3 2 14 5 3
Surveys of K540E since 2004
number of surveys 42 3 7 11 12 15 90
samples tested for K540E 6313 280 932 2392 1104 1146 12167
samples positive for 540E 3840 276 7 31 64 25 4243
surveys with >50% 540E 34 3 0 0 0 0 37
surveys with <50% 540E 8 0 7 11 12 15 53
unique sites surveyed 32 3 4 10 10 11 70
countries surveyed 9 1 2 9 5 3
Surveys of A581G
number of surveys 71 12 9 18 5 5 120
samples tested for A581G 11041 835 1220 889 275 1071 15331
samples positive for A581G 690 34 14 43 0 1 782
unique sites surveyed 45 9 4 14 4 3 79
countries surveyed 9 3 2 8 3 3
Surveys of I164L
number of surveys 103 13 21 35 5 6 183
samples tested for I164L 13393 1099 1513 1829 395 1368 19597
samples positive for I164L 78 0 1 0 0 51 130
unique sites surveyed 60 9 15 21 5 4 114
countries surveyed 10 3 2 8 3 3
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in southwest Uganda. At the more distant survey
site at Mashesha (approximately 170 km from south-
west Uganda) dhfr 164L was still absent but dhps 581
was 30%. The intensiﬁcation of resistance in both
sites predicts that SP eﬃcacy will be exceptionally
poor.
The collation of 540E data from seven recent
surveys in ﬁve diﬀerent sites in Tanzania indicated a
range in prevalence from 50% in 2005 in Chamwino
to 97% in 2007 in Korogwe District (Enevold et al.
2007; Alifrangis et al. 2009). In Korogwe, Alifrangis
et al. (2009) also reported dhps 581G at 12% but no
dhfr 164L in surveys conducted between 2003 and
2007.
In Malawi, ﬁve surveys were conducted in 2005
and 2007 in four unique sites spanning the length of
country. The prevalence of 540E reached extremes of
96%–100% (Bridges et al. 2009; Nkhoma et al. 2007).
Additionally in 2003, the prevalence of 581G was 3%
and 164L was 4% in Blantyre (Alker et al. 2005)
although both these mutations remained absent in
the other Malawian sites surveyed (Plowe et al. 1997;
Bwijo et al. 2003; Bell et al. 2008; Bridges et al. 2009;
Ochong et al. 2008).
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The picture in Zambia is mixed. Surveys in six
Zambian sites during 2004 recorded 540E preva-
lences of between 46% – 75% (Pearce et al. 2009) with
just one survey at Mpongwe falling below the 50%
prevalence cut-oﬀ. However a survey in Macha in
2006 reported prevalence of 10% 540E (Mkulama
et al. 2008). No 164L was detected in Macha
(Mkulama et al.2008) and there is no recent data on
581G. These surveys indicate limited eﬃcacy of SP in
Zambia although additional monitoring of SP resist-
ance genes including 581G are required.
InMozambique, annual surveys between 2004 and
2008 at sentinel sites across Maputo district recorded
the rise in prevalence of 540E across that region
(Raman et al. 2010). Surveys in 2004 reported
prevalences of 6% and 11%. In 2005 this increased
to 16% and in 2006 to 49%. By 2008, prevalence
exceeded 50% in all sentinel sites and the average
prevalence across the region was 65%. No dhfr 164L
or dhps 581G was found in Maputo during 2004–
2008 (Raman et al. 2010) and other studies found no
581G in other sites in Mozambique (Fernandes et al.
2007; Raman et al. 2008; Enosse et al. 2008). The
resistant genotype is well established and surveillance
at multiple sites conﬁrms this to be highly consistent
across a large geographical area.
In Madagascar, the dhps 540E was absent in 2006
(Andriantsoanirina et al. 2009) but an emerging focus
of 164L mutant alleles was reported in the south of
the country in annual surveys conducted in 2006,
2007 and 2008. Uniquely in Africa, the Malagasy
164L mutation is found as a single mutant and not in
Fig 2. Map of dhfr 164L survey sites. Countries where surveys were conducted are shaded and the survey sites are
indicated by open circles. For positive surveys the prevalence of 164L is indicated.
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combination with mutations at codons 51, 59 or 108.
In vitro assays predict that the 164L on its own will
not confer signiﬁcant resistance to pyrimethamine
(Lozovsky et al. 2009). Based on the criteria of the
50% 540E prevalence threshold there should be
no impediment to implimentation of SP-IPTi in
Madagascar. However, given the unique combi-
nation of resistance mutations and the indications of
their evolution in isolation from the mainland, it is
recommended that local assessments of SP eﬃcacy be
conducted.
InMali, there were reports of dhps 581G, one from
a survey in Bandiagara during 2000 (Thera et al.
2005) and another carried out prior to 1997 (Wang
et al. 1997). The implications of this for eﬃcacy of
SP-IPTi are unknown and unfortunately recent
surveys have not tested for 581G so the current
situation with respect to this mutation in Mali is
unknown. However the rarity of 540E in Mali was
reconﬁrmed in recent large scale surveys (Tekete
et al. 2009, Djimde et al. 2008, Dicko et al. 2010).
CONCLUSION
High level SP resistance, as indicated by the
prevalence of the 540E mutation, is advanced in
sites all across East Africa. In Ethiopia, Kenya,
Uganda, Rwanda, Tanzania, Malawi, Zambia and
Mozambique measures of the prevalence of 540E
were consistently 50% or higher since 2004. In
addition, there has been signiﬁcant intensiﬁcation of
resistance in parts of Uganda and Rwanda through
Fig 3. Map of dhps 581G survey sites. Countries where surveys were conducted are shaded and the survey sites are
indicated by open circles. For positive surveys the prevalence of 581G is indicated.
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acquisition of dhps 581G and dhfr 164L mutations.
In northern Tanzania there is a well established focus
of dhps 581G although 164L is absent. IPTi with SP
is not recommended in these areas.
Elsewhere in Africa the 540E is encountered less
frequently. Of the 36 countries for which data exists
27 have been conﬁrmed to have 540E at low
prevalence, leaving 10 countries: Burkina Faso,
Gambia, Guinea-Bissau, Ivory Coast, Liberia,
Madagascar, Mauritania, Niger, Senegal and
Equatorial Guinea where recent surveys have been
carried out but the 540E has still not been recorded.
Based on this, SP-IPTi , is still practicable through-
out much of Africa.
It will be important to maintain surveillance for
markers of SP resistance to monitor changes over the
next few years. SP has been withdrawn as a treatment
for clinical malaria and is now recommended solely
for use in intermittent preventive treatment in
pregnant women and infants With this policy change
there is expected to be a signiﬁcant reduction in drug
pressure (Malisa et al. 2010). The cumulative reports
of 540E so far have shown rising prevalence in East
Africa and a gradual spread westward (Naidoo and
Fig 4. Map showing recent measures of the prevalence of 540E. All surveys conducted since 2004 are indicted by pie
charts. The red pie charts indicate survey sites where prevalence exceeded 50% and these countries are shaded brown.
The black pie charts indicate surveys with less than 50%. Blue circles indicate zero prevalence 540E. The countries
shaded pink indicate that 540E has been detected at <50% at some stage whereas the blue ones are where it has never
been detected. White indicates countries where no data was available.
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Roper, 2010), it is likely these trends will slow or even
discontinue now that SP drug pressure is reduced.
Surveillance in support of use of SP for IPTi or
IPTp should be concentrated in areas where there is
no data and those where resistance is currently
borderline or heterogeneous. In the absence of local
information the closest approximation is to look at
resistance levels in sites in neighbouring states. For
example, in Burundi it may be expected that high
levels of SP resistance would occur because of
measures made in neighbouring sites in Rwanda
and Eastern Democratic Republic of Congo. In
situations where resistance levels are borderline,
such as the Democratic Republic of Congo and
Sudan, it may be necessary to employ district level
surveillance to inform IPTi policy at local adminis-
trative levels.
Supporting evidence of the region-wide circulation
of drug resistance genotypes comes from molecular
analysis of ﬂanking microsatellite markers around
dhps (Pearce et al. 2009) This study of resistant dhps
alleles sampled in 20 African mainland countries
showed that parasite populations are regional and
probably are linked through networks of human
circulation. Once a resistance mutation is established
at a site it can rapidly be disseminated to other
populations in the same regional genepool.
Circulation of infected people between the major
regions and between mainland and island popu-
lations is less frequent compared with their move-
ment within regions and consequently exchange of
resistance genes is more stochastic. Rogier (2005)
reported that the Djibouti-Ethiopian railway was
suspected to be an eﬀective route for propagating
malaria parasites. Both these countries lie in the
Northeast region and it is expected (but as yet
untested) that the SP resistance alleles will be
common to both countries.
The importance of parasite circulation to shared
resistance alleles among regional populations is an
implicit assumption underlying the WHO rec-
ommendations. The presence of the dhps 540E is
indicative of shared phenotype. In Madagascar, a
picture of evolution of SP resistance determinants
which was independent of the mainland emerged and
a 164L mutation was found in a novel haplotype not
recorded in mainland Africa. This illustrates an
important caution in the application of a simple
threshold prevalence of the 540E mutation. On the
mainland, it serves as a valuable approximation of
resistance levels among populations which share
common resistant alleles and in which eﬃcacy in
relation to those alleles is well understood. They are
not informative in areas where background genetics
of dhfr and dhps are signiﬁcantly diﬀerent from areas
where eﬃcacy has been evaluated. In such cases, local
evaluations of SP-IPTi eﬃcacy are required.
Alternative treatments such as artemisinin-based
combination therapies have not yet been suﬃciently
tested for safety, eﬃcacy and interactions with the
EPI to be advocated as alternatives to SP for IPTi.
So use of IPTi rests upon the continuing eﬃcacy of
SP. Our recommendations for ongoing molecular
surveillance of SP resistance markers in support of
SP-IPTi policy in Africa are three fold. First, it is
necessary that surveillance is introduced to the
neglected geographical areas and coverage increased
in countries like the Democratic Republic of Congo
which have borderline levels of 540E. Secondly,
ongoing molecular surveillance of dhps 540E should
be maintained and expanded in sites throughout
West and Central Africa in support of the continuing
use of SP for intermittent preventive treatment there.
Thirdly, monitoring of molecular markers in East
Africa should be used to record the eﬀect of reduction
in drug pressure on the prevalence of SP resistance
mutations.
ACKNOWLEDGEMENTS
We thank the database section of the Malaria Research
Programme, Medical Research Council for support
rendered.
FINANCIAL SUPPORT
The development of the drug resistance database was
supported by funding from the Gates Malaria Partnership.
The development of the website http://www.drugresistan-
cemaps.org/ipti/ was funded by the IPTi consortium.
Travel costs for CR to attend the special symposium on
paediatric parasitology were paid by the BSP.
REFERENCES
Alifrangis, M., Lusingu, J. P., Mmbando, B., Dalgaard, M. B.,
Vestergaard, L. S., Ishengoma, D., Khalil, I. F., Theander, T. G.,
Lemnge, M.M. and Bygbjerg, I. C. (2009). Five-year surveillance of
molecular markers of Plasmodium falciparum antimalarial drug resistance in
Korogwe District, Tanzania: accumulation of the 581G mutation in the
P. falciparum dihydropteroate synthase gene. American Journal of Tropical
Medicine and Hygiene 80, 523–527.
Alker, A. P., Mwapasa, V., Purﬁeld, A., Rogerson, S. J.,
Molyneux, M. E., Kamwendo, D. D., Tadesse, E., Chaluluka, E. and
Meshnick, S. R. (2005).Mutations associated with sulfadoxine-pyrimetha-
mine and chlorproguanil resistance in Plasmodium falciparum isolates from
Blantyre, Malawi. Antimicrobial Agents and Chemotherapy 49, 3919–3921.
Andriantsoanirina, V., Ratsimbasoa, A., Bouchier, C., Jahevitra, M.,
Rabearimanana, S., Radrianjafy, R., Andrianaranjaka, V.,
Randriantsoa, T., Rason, M. A., Tichit, M., Rabarijaona, L. P.,
Mercereau-Puijalon, O., Durand, R. and Menard, D. (2009).
Plasmodium falciparum drug resistance in Madagascar: facing the spread
of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroarte-
misinin susceptibility. Antimicrobial Agents and Chemotherapy 53, 4588–
4597.
Aponte, J. J., Schellenberg, D., Egan, A., Breckenridge, A.,
Carneiro, I., Critchley, J., Danquah, I., Dodoo, A., Kobbe, R.,
Lell, B., May, J., Premji, Z., Sanz, S., Sevene, E., Soulaymani-
Becheikh, R., Winstanley, P., Adjei, S., Anemana, S.,
Chandramohan, D., Issifou, S., Mockenhaupt, F., Owusu-Agyei, S.,
Greenwood, B., Grobusch, M. P., Kremsner, P. G., Macete, E.,
Mshinda, H., Newman, R. D., Slutsker, L., Tanner, M., Alonso, P.
and Menendez, C. (2009). Eﬃcacy and safety of intermittent preventive
treatment with sulfadoxine-pyrimethamine for malaria in African infants: a
pooled analysis of six randomised, placebo-controlled trials. Lancet 374,
1533–1542.
1477Maps of drug resistance markers to guide policy on SP-IPTi
Bell, D. J., Nyirongo, S. K., Mukaka, M., Zijlstra, E. E., Plowe, C. V.,
Molyneux, M. E., Ward, S. A. and Winstanley, P. A. (2008).
Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised
blinded trial to compare eﬃcacy, safety and selection of resistance inMalawi.
PLoS ONE 3, e1578.
Bonizzoni, M., Afrane, Y., Baliraine, F. N., Amenya, D. A.,
Githeko, A. K. and Yan, G. (2009). Genetic structure of Plasmodium
falciparum populations between lowland and highland sites and antimalarial
drug resistance in Western Kenya. Infection, Genetics and Evolution 9,
806–812.
Bridges, D. J., Molyneux, M. and Nkhoma, S. (2009). Low level
genotypic chloroquine resistance near Malawi’s northern border with
Tanzania. Tropical Medicine and International Health 14, 1093–1096.
Brooks, D. R., Wang, P., Read, M., Watkins, W.M., Sims, P. F. and
Hyde, J. E. (1994). Sequence variation of the hydroxymethyldihydropterin
pyrophosphokinase: dihydropteroate synthase gene in lines of the human
malaria parasite, Plasmodium falciparum, with diﬀering resistance to
sulfadoxine. European Journal of Biochemistry 224, 397–405.
Bwijo, B., Kaneko, A., Takechi, M., Zungu, I. L., Moriyama, Y.,
Lum, J. K., Tsukahara, T., Mita, T., Takahashi, N., Bergqvist, Y.,
Bjorkman, A. and Kobayakawa, T. (2003). High prevalence of quintuple
mutant dhps/dhfr genes in Plasmodium falciparum infections seven years
after introduction of sulfadoxine and pyrimethamine as ﬁrst line treatment
in Malawi. Acta Tropica 85, 363–373.
Certain, L. K., Briceno,M., Kiara, S.M., Nzila, A.M.,Watkins,W.M.
and Sibley, C. H. (2008). Characteristics of Plasmodium falciparum dhfr
haplotypes that confer pyrimethamine resistance, Kiliﬁ, Kenya, 1987–2006.
Journal of Infectious diseases 197, 1743–1751.
Chandramohan, D., Owusu-Agyei, S., Carneiro, I., Awine, T.,
Amponsa-Achiano, K., Mensah, N., Jaﬀar, S., Baiden, R.,
Hodgson, A., Binka, F. and Greenwood, B. (2005). Cluster randomised
trial of intermittent preventive treatment ofmalaria in infants in area of high,
seasonal transmission in Ghana. British Medical Journal 331, 727–733.
Cowman, A. F., Morry, M. J., Biggs, B. A., Cross, G. A. and Foote, S. J.
(1988). Amino acid changes linked to pyrimethamine resistance in the
dihydrofolate reductase-thymidylate synthase gene of Plasmodium falcipar-
um. Proceedings of the National Academy of Sciences, USA 85, 9109–9113.
Dicko, A., Sagara, I., Djimde, A. A., Toure, S. O., Traore, M.,
Dama, S., Diallo, A. I., Barry, A., Dicko, M., Coulibaly, O.M.,
Rogier, C., De Sousa, A. and Doumbo, O. K. (2010). Molecular markers
of resistance to sulphadoxine-pyrimethamine one year after implementation
of intermittent preventive treatment of malaria in infants in Mali. Malaria
Journal 9, 9.
Djimde, A. A., Fofana, B., Sagara, I., Sidibe, B., Toure, S.,
Dembele, D., Dama, S., Ouologuem, D., Dicko, A. and
Doumbo, O. K. (2008). Eﬃcacy, safety, and selection of molecular markers
of drug resistance by two ACTs in Mali. American Journal of Tropical
Medicine and Hygiene 78, 455–461.
Dunyo, S., Ord, R., Hallett, R., Jawara, M., Walraven, G., Mesa, E.,
Coleman, R., Sowe,M., Alexander, N., Targett, G. A., Pinder,M. and
Sutherland, C. J. (2006). Randomised trial of chloroquine/sulphadoxine-
pyrimethamine in Gambian children with malaria: impact against multi-
drug-resistant P. falciparum. PLoS Clinical Trials 1, e14.
Enevold, A., Nkya, W.M., Theisen, M., Vestergaard, L. S.,
Jensen, A. T., Staalsoe, T., Theander, T.G., Bygbjerg, I. C. and
Alifrangis, M. (2007). Potential impact of host immunity on malaria
treatment outcome in Tanzanian children infected with Plasmodium
falciparum.Malaria Journal 6, 153.
Enosse, S., Magnussen, P., Abacassamo, F., Gomez-Olive, X.,
Ronn, A.M., Thompson, R. and Alifrangis, M. (2008). Rapid increase
of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption
of sulphadoxine-pyrimethamine as ﬁrst line treatment in 2002, in southern
Mozambique. Malaria Journal 7, 115.
Fernandes, N., Figueiredo, P., Do Rosario, V. E. and Cravo, P. (2007).
Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations
of Plasmodium falciparum from Mozambique reveals the absence of the
dihydrofolate reductase 164L mutant. Malaria Journal 6, 35.
Francis, D., Nsobya, S. L., Talisuna, A., Yeka, A., Kamya, M. R.,
Machekano, R., Dokomajilar, C., Rosenthal, P. J. and Dorsey, G.
(2006). Geographic diﬀerences in antimalarial drug eﬃcacy in Uganda are
explained by diﬀerences in endemicity and not by knownmolecular markers
of drug resistance. Journal of Infectious Diseases 193, 978–986.
Gebru-Woldearegai, T., Hailu, A., Grobusch, M. P. and Kun, J. F.
(2005). Molecular surveillance of mutations in dihydrofolate reductase and
dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
American Journal of Tropical Medicine and Hygiene 73, 1131–1134.
Gesase, S., Gosling, R. D., Hashim, R., Ord, R., Naidoo, I.,
Madebe, R., Mosha, J. F., Joho, A., Mandia, V., Mrema, H.,
Mapunda, E., Savael, Z., Lemnge, M., Mosha, F.W.,
Greenwood, B., Roper, C. and Chandramohan, D. (2009). High
resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in
northern Tanzania and the emergence of dhps resistance mutation at Codon
581. PLoS ONE 4, e4569.
Gosling, R. D., Gesase, S., Mosha, J. F., Carneiro, I., Hashim, R.,
Lemnge, M., Mosha, F.W., Greenwood, B. and Chandramohan, D.
(2009). Protective eﬃcacy and safety of three antimalarial regimens for
intermittent preventive treatment for malaria in infants: a randomised,
double-blind, placebo-controlled trial. Lancet 374, 1521–1532.
Griﬃn, J. T., Cairns, M., Ghani, A. C., Roper, C., Schellenberg, D.,
Carneiro, I., Newman, R. D., Grobusch, M. P., Greenwood, B.,
Chandramohan, D. and Gosling, R. D. (2010). Protective eﬃcacy of
intermittent preventive treatment of malaria in infants (IPTi) using
sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE 5, e12618.
Grobusch,M. P., Egan, A., Gosling, R. D. andNewman, R. D. (2007a).
Intermittent preventive therapy for malaria: progress and future directions.
Current Opinion in Infectious Diseases 20, 613–620.
Grobusch, M. P., Lell, B., Schwarz, N. G., Gabor, J., Dornemann, J.,
Potschke, M., Oyakhirome, S., Kiessling, G. C., Necek, M.,
Langin, M. U., Klein Klouwenberg, P., Klopfer, A., Naumann, B.,
Altun, H., Agnandji, S. T., Goesch, J., Decker, M., Salazar, C. L.,
Supan, C., Kombila, D. U., Borchert, L., Koster, K. B., Pongratz, P.,
Adegnika, A. A., Glasenapp, I., Issifou, S. and Kremsner, P. G.
(2007b). Intermittent preventive treatment against malaria in infants in
Gabon – a randomized, double-blind, placebo-controlled trial. Journal of
Infectious diseases 196, 1595–1602.
Harrington, W. E., Mutabingwa, T.K., Muehlenbachs, A.,
Sorensen, B., Bolla, M. C., Fried, M. and Duﬀy, P. E. (2009).
Competitive facilitation of drug-resistant Plasmodium falciparum malaria
parasites in pregnant women who receive preventive treatment. Proceedings
of the National Academy, USA 106, 9027–9032.
Karema, C., Imwong, M., Fanello, C. I., Stepniewska, K.,
Uwimana, A., Nakeesathit, S., Dondorp, A., Day, N. P. and
White, N. J. (2010). Molecular correlates of high level antifolate resistance
in Rwandan children with Plasmodium falciparum malaria. Antimicrobial
Agents and Chemotherapy 54, 477–483.
Kobbe, R., Kreuzberg, C., Adjei, S., Thompson, B., Langefeld, I.,
Thompson, P. A., Abruquah, H. H., Kreuels, B., Ayim, M., Busch, W.,
Marks, F., Amoah, K., Opoku, E., Meyer, C. G., Adjei, O. and
May, J. (2007). A randomized controlled trial of extended intermittent
preventive antimalarial treatment in infants. Clinical Infectious Diseases 45,
16–25.
Kublin, J. G., Dzinjalamala, F. K., Kamwendo, D. D., Malkin, E.M.,
Cortese, J. F., Martino, L.M., Mukadam, R. A., Rogerson, S. J.,
Lescano, A. G., Molyneux, M. E., Winstanley, P. A., Chimpeni, P.,
Taylor, T. E. and Plowe, C. V. (2002). Molecular markers for failure of
sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of
Plasmodium falciparummalaria. Journal of Infectious Diseases 185, 380–388.
Kun, J. F., Lehman, L. G., Lell, B., Schmidt-Ott, R. and
Kremsner, P. G. (1999). Low-dose treatment with sulfadoxine-pyrimetha-
mine combinations selects for drug-resistant Plasmodium falciparum strains.
Antimicrobial Agents and Chemotherapy 43, 2205–2208.
Lozovsky, E. R., Chookajorn, T., Brown, K.M., Imwong, M.,
Shaw, P. J., Kamchonwongpaisan, S., Neafsey, D. E.,
Weinreich, D.M. and Hartl, D. L. (2009). Stepwise acquisition of
pyrimethamine resistance in the malaria parasite. Proceedings of the
National Academy of Sciences, USA 106, 12025–12030.
Lynch, C., Pearce, R., Pota, H., Cox, J., Abeku, T. A., Rwakimari, J.,
Naidoo, I., Tibenderana, J. and Roper, C. (2008). Emergence of a dhfr
mutation conferring high-level drug resistance in Plasmodium falciparum
populations from southwest Uganda. Journal of Infectious Diseases 197,
1598–1604.
Macete, E., Aide, P., Aponte, J. J., Sanz, S., Mandomando, I.,
Espasa, M., Sigauque, B., Dobano, C., Mabunda, S., Dgedge, M.,
Alonso, P. and Menendez, C. (2006). Intermittent preventive treatment
for malaria control administered at the time of routine vaccinations in
Mozambican infants: a randomized, placebo-controlled trial. Journal of
Infectious Diseases 194, 276–285.
Maiga, O., Djimde, A. A., Hubert, V., Renard, E., Aubouy, A.,
Kironde, F., Nsimba, B., Koram, K., Doumbo, O. K., Le Bras, J. and
Clain, J. (2007). A shared Asian origin of the triple-mutant dhfr allele in
Plasmodium falciparum from sites across Africa. Journal of Infectious Diseases
196, 165–172.
Malisa, A. L., Pearce, R. J., Abdulla, S., Mshinda, H., Kachur, P. S.,
Bloland, P. and Roper, C. (2010). Drug coverage in treatment of malaria
and the consequences for resistance evolution – evidence from the use of
sulphadoxine/pyrimethamine. Malaria Journal 9, 190.
1478Inbarani Naidoo and Cally Roper
Marks, F., Evans, J., Meyer, C. G., Browne, E. N., Flessner, C., Von
Kalckreuth, V., Eggelte, T. A., Horstmann, R. D. and May, J. (2005).
High prevalence of markers for sulfadoxine and pyrimethamine resistance in
Plasmodium falciparum in the absence of drug pressure in the Ashanti region
of Ghana. Antimicrobial Agents and Chemotherapy 49, 1101–1105.
McCollum, A.M., Poe, A. C., Hamel, M., Huber, C., Zhou, Z.,
Shi, Y. P., Ouma, P., Vulule, J., Bloland, P., Slutsker, L.,
Barnwell, J.W., Udhayakumar, V. and Escalante, A. A. (2006).
Antifolate resistance in Plasmodium falciparum: multiple origins and
identiﬁcation of novel dhfr alleles. Journal of Infectious Diseases 194,
189–197.
Menegon, M., Pearce, R. J., Inojosa, W. O., Pisani, V., Abel, P.M.,
Matondo, A., Bisoﬃ, Z.,Majori, G., Ord, R.,Warhurst, D. C., Roper, C.
and Severini, C. (2009). Monitoring for multidrug-resistant Plasmodium
falciparum isolates and analysis of pyrimethamine resistance evolution in
Uige province, Angola. Tropical Medicine and International Health 14,
1251–1257.
Mkulama,M. A., Chishimba, S., Sikalima, J., Rouse, P., Thuma, P. E.
and Mharakurwa, S. (2008). Escalating Plasmodium falciparum antifolate
drug resistance mutations in Macha, rural Zambia.Malaria Journal 7, 87.
Mockenhaupt, F. P., Reither, K., Zanger, P., Roepcke, F., Danquah, I.,
Saad, E., Ziniel, P., Dzisi, S. Y., Frempong, M., Agana-Nsiire, P.,
Amoo-Sakyi, F., Otchwemah, R., Cramer, J. P., Anemana, S. D.,
Dietz, E. and Bienzle, U. (2007). Intermittent preventive treatment in
infants as a means of malaria control: a randomized, double-blind, placebo-
controlled trial in northern Ghana. Antimicrobial Agents and Chemotherapy
51, 3273–3281.
Mockenhaupt, F. P., Teun Bousema, J., Eggelte, T. A., Schreiber, J.,
Ehrhardt, S.,Wassilew,N., Otchwemah, R. N., Sauerwein, R.W. and
Bienzle, U. (2005). Plasmodium falciparum dhfr but not dhps mutations
associated with sulphadoxine-pyrimethamine treatment failure and game-
tocyte carriage in northern Ghana. Tropical Medicine and International
Health 10, 901–908.
Naidoo, I. and Roper, C. (2010). Following the path of most resistance:
dhps K540E dispersal in African Plasmodium falciparum. Trends in
Parasitology 26, 447–456.
Ndounga,M., Tahar, R., Basco, L. K., Casimiro, P. N.,Malonga, D. A.
and Ntoumi, F. (2007). Therapeutic eﬃcacy of sulfadoxine-pyrimetha-
mine and the prevalence of molecular markers of resistance in under 5-year
olds in Brazzaville, Congo. Tropical Medicine and International Health 12,
1164–1171.
Nkhoma, S., Molyneux, M. andWard, S. (2007). Molecular surveillance
for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Tropica
102, 138–142.
Ochong, E., Bell, D. J., Johnson, D. J., D’alessandro, U., Mulenga, M.,
Muangnoicharoen, S., Van Geertruyden, J. P., Winstanley, P. A.,
Bray, P. G., Ward, S. A. and Owen, A. (2008). Plasmodium falciparum
strains harboring dihydrofolate reductase with the I164L mutation are
absent in Malawi and Zambia even under antifolate drug pressure.
Antimicrobial Agents and Chemotherapy 52, 3883–3888.
Omar, S. A., Adagu, I. S. and Warhurst, D. C. (2001). Can pretreatment
screening for dhps and dhfr point mutations in Plasmodium falciparum
infections be used to predict sulfadoxine-pyrimethamine treatment failure?
Transactions of the Royal Society of Tropical Medicine and Hygiene 95,
315–319.
Pearce, R. J., Pota, H., Evehe, M. S., Ba El, H., Mombo-Ngoma, G.,
Malisa, A. L., Ord, R., Inojosa, W., Matondo, A., Diallo, D. A.,
Mbacham, W., Van Den Broek, I. V., Swarthout, T. D.,
Getachew, A., Dejene, S., Grobusch, M. P., Njie, F., Dunyo, S.,
Kweku, M., Owusu-Agyei, S., Chandramohan, D., Bonnet, M.,
Guthmann, J. P., Clarke, S., Barnes, K. I., Streat, E., Katokele, S. T.,
Uusiku, P., Agboghoroma, C. O., Elegba, O. Y., Cisse, B., Ie, A. E.,
Giha, H. A., Kachur, S. P., Lynch, C., Rwakimari, J. B., Chanda, P.,
Hawela,M., Sharp, B., Naidoo, I. andRoper, C. (2009).Multiple origins
and regional dispersal of resistant dhps in African Plasmodium falciparum
malaria. PLoS Medicine 6, e1000055.
Peterson, D. S., Walliker, D. andWellems, T. E. (1988). Evidence that a
point mutation in dihydrofolate reductase-thymidylate synthase confers
resistance to pyrimethamine in falciparum malaria. Proceedings of the
National Academy of Sciences, USA 85, 9114–9118.
Plowe, C. V., Cortese, J. F., Djimde, A., Nwanyanwu, O. C.,
Watkins, W.M., Winstanley, P. A., Estrada-Franco, J. G.,
Mollinedo, R. E., Avila, J. C., Cespedes, J. L., Carter, D. and
Doumbo, O. K. (1997). Mutations in Plasmodium falciparum dihydrofolate
reductase and dihydropteroate synthase and epidemiologic patterns of
pyrimethamine-sulfadoxine use and resistance. Journal of Infectious diseases
176, 1590–1596.
Raman, J., Little, F., Roper, C., Kleinschmidt, I., Cassam, Y.,
Maharaj, R. and Barnes, K. I. (2010). Five years of large-scale dhfr and
dhps mutation surveillance following the phased implementation of
artesunate plus sulfadoxine-pyrimethamine in Maputo Province,
Southern Mozambique. American Journal of Tropical Medicine and
Hygiene 82, 788–794.
Raman, J., Sharp, B., Kleinschmidt, I., Roper, C., Streat, E., Kelly, V.
and Barnes, K. I. (2008). Diﬀerential eﬀect of regional drug pressure on
dihydrofolate reductase and dihydropteroate synthetase mutations in
southern Mozambique. American Journal of Tropical Medicine and
Hygiene 78, 256–261.
Rogier, C., Pradines, B., Bogreau, H., Koeck, J. L., Kamil, M. A. and
Mercereau-Puijalon, O. (2005). Malaria epidemic and drug resistance,
Djibouti. Emerging Infectious Diseases 11, 317–321.
Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F. and Anderson, T.
(2004). Intercontinental spread of pyrimethamine-resistant malaria. Science
305, 1124.
Schellenberg, D., Menendez, C., Aponte, J. J., Kahigwa, E.,
Tanner, M., Mshinda, H. and Alonso, P. (2005). Intermittent preventive
antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a
randomised, placebo-controlled trial. Lancet 365, 1481–1483.
Schellenberg, D., Menendez, C., Kahigwa, E., Aponte, J., Vidal, J.,
Tanner, M., Mshinda, H. and Alonso, P. (2001). Intermittent
treatment for malaria and anaemia control at time of routine vaccinations
in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357,
1471–1477.
Schunk,M., Kumma,W. P.,Miranda, I. B., Osman,M. E., Roewer, S.,
Alano, A., Loscher, T., Bienzle, U. and Mockenhaupt, F. P. (2006).
High prevalence of drug-resistance mutations inPlasmodium falciparum and
Plasmodium vivax in southern Ethiopia. InMalaria Journal 5, 54.
Staedke, S. G., Sendagire, H., Lamola, S., Kamya, M. R., Dorsey, G.
and Rosenthal, P. J. (2004). Relationship between age, molecular markers,
and response to sulphadoxine-pyrimethamine treatment in Kampala,
Uganda. Tropical Medicine and International Health 9, 624–629.
Tekete, M., Djimde, A. A., Beavogui, A. H., Maiga, H., Sagara, I.,
Fofana, B., Ouologuem, D., Dama, S., Kone, A., Dembele, D.,
Wele, M., Dicko, A. and Doumbo, O. K. (2009). Eﬃcacy of chloroquine,
amodiaquine and sulphadoxine-pyrimethamine for the treatment of
uncomplicated falciparum malaria: revisiting molecular markers in an area
of emerging AQ and SP resistance in Mali. Malaria Journal 8, 34.
Thera, M. A., Sehdev, P. S., Coulibaly, D., Traore, K., Garba, M.N.,
Cissoko, Y., Kone, A., Guindo, A., Dicko, A., Beavogui, A. H.,
Djimde, A. A., Lyke, K. E., Diallo, D. A., Doumbo, O. K. and
Plowe, C. V. (2005). Impact of trimethoprim-sulfamethoxazole prophylaxis
on falciparum malaria infection and disease. Journal of Infectious Diseases
192, 1823–1829.
Triglia, T. and Cowman, A. F. (1994). Primary structure and expression
of the dihydropteroate synthetase gene of Plasmodium falciparum.
Proceedings of the National Academy of Sciences, USA 91, 7149–7153.
Triglia, T., Menting, J. G., Wilson, C. and Cowman, A. F. (1997).
Mutations in dihydropteroate synthase are responsible for sulfone and
sulfonamide resistance in Plasmodium falciparum. Proceedings of the
National Academy of Sciences, USA 94, 13944–13949.
Wang, P., Lee, C. S., Bayoumi, R., Djimde, A., Doumbo, O.,
Swedberg, G., Dao, L. D., Mshinda, H., Tanner, M.,
Watkins, W.M., Sims, P. F. and Hyde, J. E. (1997). Resistance to
antifolates in Plasmodium falciparum monitored by sequence analysis of
dihydropteroate synthetase and dihydrofolate reductase alleles in a large
number of ﬁeld samples of diverse origins. Molecular and Biochemical
Parasitology 89, 161–177.
WHO (2009). Technical Consultation on Intermittent Preventive
Treatment in Infants (IPTi),Technical Expert Group on Preventive
Chemotherapy.WHO TEG IPTi Report April 2009. World Health
Organisation pp. 1–11.
Zhong, D., Afrane, Y., Githeko, A., Cui, L., Menge, D.M. and Yan, G.
(2008). Molecular epidemiology of drug-resistant malaria in western Kenya
highlands. In BMC Infectious Diseases 8, 105.
1479Maps of drug resistance markers to guide policy on SP-IPTi
